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Abstract: To mount a strong anti-tumor immune response, non T cell inflamed (cold) tumors may
require combination treatment encompassing vaccine strategies preceding checkpoint inhibition.
In vivo targeted delivery of tumor-associated antigens (TAA) to dendritic cells (DCs), relying on
the natural functions of primary DCs in situ, represents an attractive vaccination strategy. In this
study we made use of a full-length MART-1 expressing C/B-chimeric adenoviral vector, consisting of
the Ad5 capsid and the Ad3 knob (Ad5/3), which we previously showed to selectively transduce
DCs in human skin and lymph nodes. Our data demonstrate that chimeric Ad5/3 vectors encoding
TAA, and able to target human DCs in situ, can be used to efficiently induce expansion of functional
tumor-specific CD8+ effector T cells, either from a naïve T cell pool or from previously primed
T cells residing in the melanoma-draining sentinel lymph nodes (SLN). These data support the use of
Ad3-knob containing viruses as vaccine vehicles for in vivo delivery. “Off-the-shelf” DC-targeted Ad
vaccines encoding TAA could clearly benefit future immunotherapeutic approaches.
Keywords: melanoma; adenovirus (Ad)5/3; dendritic cell targeting; melanoma-specific T cells;
MART-1; sentinel lymph node
1. Introduction
The long-term survival rates for patients with metastatic malignant melanoma have dramatically
increased over the past seven years with the effective clinical targeting of immune checkpoints
like CTLA-4 and PD-1 [1–3]. With these successes, also the understanding arose of the importance
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of an inflammatory immune infiltrate in the tumor microenvironment for the clinical efficacy of
these immunotherapies [4]. Patients who do not have a so-called “T cell inflamed/hot” tumor
microenvironment, are less likely to respond to immune checkpoint blockade and may require
a “priming therapy”, such as an anti-cancer vaccine, to kick-start the cancer immunity cycle [5].
Due to their unique ability to orchestrate T- and B-cell immunity, dendritic cells (DCs) are
attractive targets for the delivery of vaccines. As professional antigen presenting cells (APCs) of the
immune system, DCs are highly specialized in capturing, processing and presenting antigens to naive
lymphocytes. For this purpose, DCs patrol the peripheral tissues to detect and take up antigens and,
provided they receive sufficient maturation-inducing stimuli, then migrate into the paracortical areas
of draining lymph nodes (LN) to engage and prime specific T cells.
The well-known and often used melanoma tumor-associated antigen (TAA), MART-1/Melan-A is
an immunogenic self-antigen expressed in both normal and malignant melanocytes. While justifiably
much of ongoing research focuses on patient-specific neo-epitopes as attractive antigens to target [6,7],
over-expressed shared tumor antigens should not be disregarded as vaccine targets. In metastatic
melanoma, it has been reported that the majority of tumor-infiltrating lymphocytes (TILs) derived
from HLA-A2 positive patients were able to recognize the immunodominant epitope of MART-1,
i.e., the fragment of the protein consisting of the amino acids 26–35 (MART-126–35) [8]. Optimal
delivery of TAAs to DCs is crucial for the enhancement of their therapeutic potential. Ex vivo modified
autologous DCs have been used as melanoma vaccines to improve anti-tumor immunity [9,10].
However, laborious, expensive, and time-consuming ex vivo generation of DCs as well as their poor
in vivo migration, often complicate their clinical utility and impair their efficacy [11,12]. An attractive
alternative approach is based on the delivery of TAAs directly to tissue resident DCs in situ. In vivo
targeting of DCs takes advantage of their intrinsic migratory and T cell stimulatory capacities.
Numerous approaches have been designed for targeting DCs in vivo using vehicles such as monoclonal
antibodies, nanoparticles, viruses, or liposomes in order to deliver the TAA of choice [13–17].
Adenoviruses (Ads) appear to be ideal vaccine vehicles as they can be genetically modified
to stably carry large transgenes in their genome that remain episomal in the transduced host cells,
minimizing the possibility of insertional mutagenesis [18]. Replication-deficient Ads can be easily
propagated in high titers, enhancing their safety for in vivo use and simultaneously profiting of
potentially immune-activating viral components that can function as vaccine adjuvant. Moreover,
Ads can efficiently transduce both replicating and non-replicating cells [8] and induce robust humoral
and cellular antitumor immune responses in vitro and in vivo [19–21]. Serotype-5 recombinant
adenovirus (Ad5) encoding TAAs has been widely used as vehicle for gene transfer to human DCs [22].
As a member of the subgroup C adenoviruses, Ad5 binds to the cocksackie- and adenovirus receptor
(CAR) as a primary docking receptor prior to infection, and uses integrin docking via hexon proteins
for internalization. It has already been shown that recombinant Ad5 can act synergistically with
maturation-inducing signals to generate highly immunostimulatory APCs [22]. However, DCs are
relatively refractory to Ad5 transduction due to low levels or even lack of CAR expression on their
cell surface [23]. In contrast, CAR is present at the surface of a wide variety of bystander cells [24].
To efficiently transduce DCs, Ad5 vectors need to be administered in vivo at high titers, which may
also lead to the transduction of non-professional APCs and consequently result in sub-efficient T cell
activation, T cell anergy or even induction of specific tolerance to the inserted transgene product [25].
Systemic use of Ad5 vector is also restrained due to a high prevalence of pre-existing immunity against
this vector (in 50–90% of the population) [26]. To enhance the therapeutic potency and minimize
unwanted side effects, new adenoviral vectors with broadened tropism are being developed [27] that
allow redirecting of the adenovirus to target receptors that are highly, and selectively expressed on the
surface of DCs.
Adenovirus-3 (Ad3) has been described to bind to the co-stimulatory molecules CD80 (B7.1)
and CD86 (B7.2) on human monocyte-derived DCs (MoDCs) [28]. We previously analyzed a panel
of different subgroup B/C chimeric and fiber-modified Ads, and compared them for their relative
Vaccines 2018, 6, 42 3 of 17
capacity to transduce human DCs [29]. The C/B-chimeric adenovirus serotype 5 (Ad5)/3, consisting
of Ad5 fiber and Ad3 knob, was selected for its high-efficiency (skin) DC-transduction through
binding to the B7-family members CD80/CD86 without interrupting subsequent T cell stimulation
and proliferation. Ad5/3 was superior to Ad5 in the transduction of in vitro generated mature MoDCs,
as well as the specific targeting of mature human myeloid DCs emigrated from skin (Langerhans
cells and dermal DC) and residing in melanoma skin-draining lymph nodes (LN). Due to their
more specific tropism, Ad3-based vectors may be less likely to infect non-professional APCs and
cause undesirable side effects such as immune tolerance. The sentinel lymph node (SLN), as the
first tumor-draining LN, is considered to be the most probable site of initial micrometastasis and is
characterized by profound tumor-induced immune suppression. Also, the SLN is the primary site
where naïve T cells are primed for the recognition of TAA by tumor antigen presenting, activated
DCs. The generation of effective T cell mediated immunity in SLN is crucial for the elimination of
metastases [30,31]. Whereas Ad5-based vaccines can often only be applied once, as an immediate
induced or enhanced Ad-specific immune response will neutralize a booster vaccine [32], heterologous
prime-boost vaccines incorporating Ad-based vaccines have been shown to be an appealing strategy
for DC-targeted vaccination [33–35]. In this respect, vaccines based on alternative serotypes, such as
the subgroup B1 adenovirus Ad3, with lower pre-existing immunity, might be particularly good
candidates for such an approach.
In this study, DCs derived either from in vitro differentiated monocytes or ex vivo from
melanoma-draining SLN were transduced with CD80/CD86-targeted fiber-modified Ad5/3 encoding
full-length MART-1. Our main aim was to evaluate whether transduction of DCs by this chimeric,
MART-1 expressing Ad5/3 could lead to the priming and activation of melanoma-specific CD8+ T
effector cells. More importantly, we determined whether this vector could effectively target APCs
in SLN of melanoma patients in order to enhance the frequencies of tumor-reactive effector CD8+ T
cells. We compared the priming capacity of DCs transduced by the Ad5/3-MART-1 vector to DCs
transduced by the Ad5-MART-1. Our findings suggest that an “off-the-shelf” DC-targeted Ad3-based
vaccine could benefit future immunotherapeutic approaches by increasing tumor-antigen specific
CD8+ effector cells both in tumor-draining SLNs and systemically, that could next be unleashed in
their proliferation and killing capacity by immune checkpoint blockade.
2. Materials and Methods
2.1. Cell Lines
The melanoma cell lines Mel-AKR (MART-1+ HLA-A2+) and Mel-JKO (MART-1+ HLA-A2−)
(Netherlands Cancer Institute, Amsterdam, The Netherlands) and the human glioblastoma cell
line U251 (MART-1− HLA-A2+) were cultured in Dulbecco’s Modified Eagle Medium (DMEM;
Lonza, Verviers, Belgium) supplemented with 10% fetal calf serum (FCS; HyClone), 100 IU/mL
sodium-penicillin, 100 µg/mL streptomycin, 2 mM L-glutamine, and 50 µM β-mercaptoethanol (2ME)
(complete medium). The Epstein Bar virus (EBV)-transformed HLA-A2+ B-cell line JY was cultured in
Iscove’s modified Dulbecco’s medium (IMDM; Lonza, Verviers, Belgium) complete medium.
2.2. Monocyte-Derived DC Generation
Peripheral blood mononuclear cells (PBMCs) from HLA-A2+ healthy donors were isolated
from buffy coats obtained from Sanquin blood supply foundation (Amsterdam, The Netherlands)
using density gradient centrifugation over Ficoll as described in [36]. CD14+ monocytes were
isolated from PBMCs by positive labeling using magnetic bead-conjugated anti-CD14 antibody
(Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer’s protocol. Isolated
monocytes were cultured in IMDM complete medium supplemented with 1000 IU/mL recombinant
human granulocyte colony stimulating factor (rhGM-CSF; Leukine, Berlex, Seattle, WA, USA)
and 10 ng/mL interleukin-4 (IL-4; R&D systems, Abingdon, England, UK) over 5 to 6 days for
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the generation of immature DC. MoDCs were matured by culturing them for two more days
in IMDM complete medium supplemented with a cocktail of maturation inducing cytokines: 10
ng/mL interleukin-6 (IL-6) (R&D Systems, Minneapolis, MN, USA), 1 µg/mL prostaglandin E2
(PGE2) (Sigma-Aldrich, Zwijndrecht, The Netherlands), and 25 ng/mL interleukin-1 beta (IL-1 beta)
(Miltenyi Biotec), 2400 IU/mL tumor necrosis factor- alpha (TNFa) (Miltenyi Biotec).
2.3. Flow Cytometric Phenotypic Analyses
The MoDC phenotype was assessed using CD1a fluorescein-5-isothiocyanate (FITC)- and CD14
PerCP-labeled monoclonal antibodies (mAbs). To ascertain MoDC maturation, Phycoerythrin
(PE)-labeled mAbs directed against human CD86 (BD Pharmingen, San Jose, CA, USA; 1:50) were
used as well as isotype-matched control mAbs. Approximately 5 × 104 cells were washed in
phosphate-buffered saline (PBS) supplemented with 0.02% sodium azide (NaN3) and 0.1% bovine
serum albumin (BSA), and incubated with the specific mAb for 30 min at 4 ◦C.
PE-labeled HLA-A2 tetramers (Tm) presenting the MART-126–35L epitope were produced as
described previously [37] and were used for cytofluorometric analysis of primed CD8+ T cells
(generated as described below [38]). Tm staining was performed for 20 min at 37 ◦C, followed
by incubation with FITC-labeled mAbs against CD8 (BD Biosciences, San Jose, CA, USA; 1:100).
Dead cells were excluded by adding 0.5 µg/mL propidium iodide (ICN Biomedicals, Zoetermeer,
The Netherlands). Stained cells were measured on a FACSCaliburTM flow cytometer (BD Biosciences,
Franklin Lakes, NJ, USA) and data were analyzed by the Cell QuestPro software.
2.4. Generation of Adenoviral Vectors
The Ad5-MART-1 vector was used and described previously [39]. To generate
Ad5/3-MART-1, pShuttle-CMV-MART-1 was constructed and recombined with Ad5/3
backbone (pVK903K) plasmid. In order to generate pShuttle-CMV-MART-1, PCR was
used to incorporate SalI and NotI sites onto the MART-1 cDNA. The following primers
were used: SalI Forward Mart-1: GCGAAGTCGACATGCCAAGAGAAGATGCT and NotI
reverse-TGCTCGGCGGCCGCTTAAGGTGAATAAGGT. The resulting PCR product was digested
with SalI and NotI restriction enzymes, along with pShuttle-CMV plasmid. The MART-1 fragment
was cloned into the pShuttle-CMV plasmid and the resultant pShuttle-CMV-MART-1 plasmid was
sequenced for verification. pShuttle-CMV-MART-1 was linearized with PmeI restriction enzyme.
The recombination of Ad5/3 backbone (pVK903K) plasmid and linearized pShuttle-CMV-MART-1
was performed in Escherichia coli BJ5183 (Stratagene, CA, USA), leading to the identification of positive
vector clones by means of PCR and sequencing.
To rescue the vector, the recombinant adenoviral genome was digested with PacI, and transfected
into the Ad5-E1-expressing HEK293 cells using Lipofectamine 2000 Reagent (ThermoFisher
Scientific, Waltham, MA, USA). Multi-step large-scale propagations of recombinant Ad5 vector were
performed after the vector was rescued. Rescued viruses were purified by double cesium chloride
ultracentrifugation and dialyzed against phosphate buffered saline without Mg2+ or Ca2+ and with
10% glycerol. Viruses were stored at −80 ◦C until use. To titrate the purified vectors, physical titers,
expressed as viral particles (VPs) per mL were measured using absorbance at 260 nm.
2.5. In Vitro Ad Transduction
Replication-deficient Ad5 and Ad5/3 viruses were used for MoDC transduction. These viruses
were encoding either green fluorescent protein (GFP) or full length MART-1. In vitro-generated
mature MoDC (1 × 105) were transduced with the adenoviruses at a multiplicity of infection (MOI)
of 1000 viral particles (VP). In short, mature MoDCs were resuspended in 500 µL serum free IMDM
supplemented with 100 IU/mL sodium-penicillin, 100 µg/mL streptomycin, 2 mM L-glutamine and
50 µM β-mercaptoethanol (2ME). The indicated Ad were then added to the cells and incubated at
37 ◦C and 5% CO2. In two out of four experiments, Ad-5-MART-1 viruses were first complexed
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with lipofectamine (Invitrogen, Carlsbad, CA, USA) as described previously [39] to achieve MoDC
transduction efficiencies comparable to described Ad5/3 transduction efficiencies [29] independent of
the low expression levels of the Ad5 docking receptor CAR. After 2 h, IMDM complete medium was
added to the cells. For eGFP read-out, transduced MoDCs were harvested 48 h later and analyzed for
GFP transgene expression in combination with CD86-PE labeled activation marker by flow cytometry as
described above (Becton-Dickinson CO, Franklin Lakes, NJ, USA). MoDCs transduced by Ad-MART-1
were used to induce or re-stimulate MART-1-specific CD8+ T cells after 24 h of culture.
2.6. In Vitro Induction of MART-1-Specific CD8+ Effector T Cell
CD8β+ T cells were isolated from PBMC of HLA-A2+ healthy donors by positive labeling
with anti-CD8β antibody (Beckman Coulter, Brea, CA, USA) and goat-anti-mouse (GaM) magnetic
beads (Miltenyi Biotec) using a magnetic cell-sorting device (Miltenyi Biotec) according to the
manufacturer’s protocol. In order to induce MART-1-specific cytotoxic T lymphocytes (CTLs),
1 × 106 CD8β+ T cells and 1 × 106 irradiated (10 Gy) CD8β− autologous PBMC were co-cultured
with 1 × 105 Ad5-, lipofectamine-complexed Ad5- or Ad5/3-transduced DCs for 10 days in Yssel’s
medium [40] supplemented with 1% hAB serum (ICN Biochemicals, Zoetermeer, The Netherlands)
in the presence of 10 ng/mL IL-6 and 10 ng/mL IL-12 in a 24-well tissue-culture plate. For each
donor, six equivalent cultures were initiated per condition. On Day 1 after the start of the experiment,
10 ng/mL IL-10 (R&D Systems, Minneapolis, MN, USA) was added to the cells. From Day 10,
CD8+ T cell cultures were stimulated every week for 2–3 weeks with 1 × 105 freshly transduced
autologous MoDCs in the presence of 5 ng/mL IL-7 (Strathmann Biotec, Hamburg, Germany). On the
day of each re-stimulation, a sample of each culture was used to determine the frequencies of
MART-126–35L Tm-binding CD8+ T cells in the bulk cultures. Two days after each re-stimulation,
10 IU/mL IL-2 (Strathmann Biotec) was added. MART-126–35L Tm+ CD8+ T cell were then isolated by
magnetic Tm+ flow sorting using PE-labeled Tm and anti-PE magnetic beads (Miltenyi Biotec) in order
to expand a specificity-enriched bulk population. To this end, sorted CD8+ T cell were stimulated each
week with irradiated (10 Gy) feeder-mixes composed of allogeneic PBMCs from two different donors
(2:1 ratio with CD8+ T cells) and JY cells (1:5 ratio with CD8+ T cells) in Yssel’s medium supplemented
with 100 ng/mL phytohemagglutinin (PHA, from Murex Biotech, Dartford, UK) and 10 IU/mL IL-7.
CD8+ T cell bulks were subsequently tested in different functional assays. Using the same procedure,
MART-1 CD8+ T cell bulks were derived by (re-)stimulating with MART-126–35L peptide-loaded MoDC,
as previously described [39].
2.7. Preparation, Transduction and Culture of Sentinel Lymph Node Single-Cell Suspensions
Single-cell suspensions from human SLNs were obtained from melanoma patients after their
informed consent without interference in standard diagnostic procedures as described previously [41].
This protocol was approved by the Institute’s Medical ethical committee (IRB) and in accordance
with the Declaration of Helsinki. In brief, SLN were bisected in a sterile environment and viable cells
were scraped from the SLN cutting surface. SLN cells were then collected in 15 mL sterile ice-cold
dissociation medium comprising IMDM medium with 25 mM HEPES buffer (BioWhittaker, Verviers,
Belgium) supplemented with 5% FCS, 100 IU/mL sodium-penicillin, 100 µg/mL streptomycin, 2 mM
L-glutamine, 0.1% DNAse, and 0.14% Collagenase A (Roche Nederland BV, Woerden, The Netherlands).
Scraped cells were transferred to sterile glass flasks containing a stirring bean in a total volume of 30 mL
dissociation medium and were placed on a magnet for 45 min at 37 ◦C in a water bath. Subsequently,
the SLN cells were filtered over a 100 µM sterile cell strainer (BD Biosciences) into 50 mL tubes. Flasks
were rinsed twice with IMDM complete medium. After centrifugation (1560 rpm for 5 min) single
cell suspensions were counted, and further processed. The SLN cells were first tested for HLA-A2
expression by flow cytometry. SLN cells derived from HLA-A2+ melanoma patients were seeded at
a density of 1 × 106 cells/well of a 24-well plate in 500 µL serum-free medium. SLN cells were then
transduced with Ad5/3-MART-1 or Ad5-MART-1 at a MOI of 1000 viral particles based on calculated
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absolute SLN-DC numbers as described previously [29]. After 2 h of transduction at 37 ◦C, 2 mL of
Yssel’s medium was added to the cells supplemented with 10 ng/mL of IL-7 and cells were cultured for
10 days. The frequencies of MART-126–35L Tm-binding CD8+ T cells were subsequently measured by
flow cytometry. For re-stimulation at Day 10, 0.1 × 106 HLA-A2+ JY cells per bulk culture were loaded
with 10 ng/mL MART-126–35L peptide in the presence of 3 µg/mL β2-microglobulin (Sigma-Aldrich)
in serum free medium and after loading were washed and added to the cultures. Two days after
re-stimulation, 10 ng/mL IL-2 and IL-15 were added to the cells.
2.8. Intracellular Interferon γ (IFN-γ) Detection
To evaluate the ability of the generated CD8+ T cell to produce IFN-γ upon recognition of
a particular target cell, intracellular IFN-γ staining was performed. The melanoma tumor cell lines
Mel-AKR, Mel-JKO and the glioblastoma cell line U251 were used as target cells, as well as JY cells
loaded with either the relevant MART-126–35L peptide or an irrelevant (HIV) peptide. Resting CD8+
T cells that had not been stimulated for at least one week were co-cultured with target cells at an
effector:target cell (E:T) ratio of 2:1 in 96-well round-bottom plates in the presence of GolgiPlug
(BD Biosciences). After 4–5 h of stimulation, cells were washed and labeled with PE-conjugated
MART-1 tetramers and APC-conjugated anti-CD8 mAb. The BD Cytofix/Cytoperm (BD Biosciences)
kit was used according to the manufacturer’s protocol for intracellular staining with FITC-labeled
anti-IFNγ Ab (BD Biosciences) and analyzed on a FACSCalibur (BD Biosciences).
2.9. Functional Avidity Analysis
To determine the functional avidity of the induced MART-1 specific CD8+ T cells generated by
Ad5/3-MART-1, intracellular IFN-γ staining was performed as described above. Ad5/3-MART-1
primed and tetramer-MACS-isolated MART-1 specific CD8+ T cells were compared with control
MART-126–35L peptides primed and MACS-isolated MART-1 specific CD8+ T cells, due to frequencies
of MART-1 specific CD8+ T cells induced with the Ad5-MART-1 virus that were too low to perform
these functional assays. HLA-A2+ JY cells were used as stimulator cells after being loaded with serial
1000-fold dilutions (10 µM, 10 nM, 10 pM, 10 fM, and no peptide) of the MART-126–35L peptide and
were co-cultured with CD8+ T effector cells at effector:stimulator (E:S) ratios of 1:1. IFN-γ production
of stimulated CD8+ T cells was evaluated by flow cytometry after staining with PE-conjugated MART-1
tetramer, APC-conjugated CD8 and intracellular staining of FITC-labeled IFN-γ. For visualization,
the percentages of IFN-γ producing CD8+ T cells at the highest peptide concentration of 10 µM were
set at 100% for both conditions.
2.10. Cytotoxicity Assay
The cytolytic activity of MART-1-specific CD8+ T cells was evaluated by a flow cytometry-based
cytotoxicity assay. For this purpose, MACS isolated effector CD8+ T cells were labeled with 200 nM
CFSE (Molecular Probes, Eugene, OR, USA) for 15 min at 37 ◦C, washed twice, and co-cultured with
target cells at 10:1 and 3:1 E:T ratios in a 48-well plate. The melanoma tumor cell lines Mel-AKR
(HLA-A2+ MART-1+), and Mel-JKO (HLA-A2− MART-1+) were used as target cells. After 4 to 5 h at
37 ◦C, target cells were harvested and stained with 7-amino actinomycin D (7-AAD) (Sigma Aldrich,
Saint Louis, MO, USA) for 10 min at 4 ◦C to distinguish necrotic cells. Acquisition was performed on
a FACSCalibur and specific lysis was calculated as described previously [39].
2.11. Statistical Analysis
Data were analyzed by two-tailed, paired, or unpaired Student t test, or one-way or two-way
ANOVA with Tukey post-hoc analysis as indicated in the text using GraphPad Prism 6.0 software
(GraphPad Software, La Jolla, CA, USA). Differences were considered significant when p < 0.05.
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3. Results
3.1. Superior Efficiency of MART-126–35 Specific CD8+ T Cell Priming by Ad5/3-MART-1 Transduced MoDCs
as Compared to Ad5-MART-1 Transduced MoDCs
We investigated the capability of autologous mature MoDCs transduced by MART-1 encoding
Ad5/3 to prime TAA-specific, HLA-A2restricted CTL. Ad5/3 and Ad5 vectors encoding the
full-length MART-1 antigen were used for transduction of mature MoDCs (MOI 1000 vp). To obtain
comparable transduction efficiencies between Ad5-MART-1 and Ad5/3-MART-1, an additional control
transduction was taken along in two experiments, complexing Ad5-MART-1 to lipofectamine prior
to MoDC transduction [39]. As a read-out, we used a fluorescently labeled tetramer recognizing
the high-affinity altered-peptide ligand for the immune-dominant MART-1 epitope MART-126–35;
the MART-126–35L [42]. MART-126–35L-specific T cells could be detected at higher frequencies in
cultures stimulated with MoDCs transduced by Ad5/3-MART-1 compared to Ad5-MART-1 or
lipofectamine-complexed Ad5-MART-1 after the induction phase and after the first re-stimulation
(Figure 1a). After two rounds of in vitro re-stimulation with Ad-transduced autologous MoDCs,
the frequencies of MART-1-specific CD8+ T cells stimulated by Ad5/3-MART-1 transduced MoDCs
were slightly further increased as shown for a representative donor (Figure 1a) and combined data for
four donors (Figure 1b).
Figure 1. Ad5/3-MART-1 transduced monocyte-derived dendritic cells (MoDCs) more efficiently prime
and expand MART-1 Tm+ CD8+ T cells than Ad5-MART-1 transduced MoDC. (a) MART-1 induction
and re-stimulation results of a representative donor using mature MoDC transduced with Ad5-MART-1,
Lipofectamine (Li)-complexed Ad5-MART-1 or Ad5/3-MART-1. Six bulk cultures were started for
each condition. Frequencies of Tm+ (MART-126–35L) CD8+ T cells were analyzed on Day 10 (induction),
Day 18 (1st re-stim) and Day 25 (2nd re-stim). One-way ANOVA with Tukey multiple comparison
analyses was performed to determine statistical significance. (b) Combined data for Ad5-MART-1
versus Ad5/3-MART-1 priming from n = 4 experiments with six bulk cultures per condition per
experiment. Unpaired Student t-tests were performed between Ad5-MART-1 and Ad5/3-MART-1
conditions for each time point.
3.2. T Cells Primed with Ad5/3-MART-1 Transduced MoDCs Recognize Endogenously Processed MART-1
To evaluate the functionality of the MART-1-specific CD8+ T cells, we assessed their ability to
recognize endogenously processed MART-1 epitopes. For this purpose, the MART-1-specific CD8+
T cells that were induced by stimulation with Ad5-MART-1 or Ad5/3-MART-1 transduced or obtained
after priming and restimulation with control MART-126–35L peptide loaded MoDCs were isolated
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by magnetic MART-126–35L Tm PE sorting and were expanded by several rounds of re-stimulation
with feeder-mix. Of note, insufficient numbers of specific CD8+ T cells were obtained through this
method for Ad5-MART-1-transduced MoDCs to perform all functional analyses. CD8+ T cells were
co-cultured for 4 h with different target cells: a MART-1+ HLA-A2+ cell line (Mel-AKR), a MART-1+
HLA-A2− cell line (Mel-JKO), a MART-1− HLA-A2+ cell line (U251), and HLA-A2+ JY cells loaded
with MART-126–35L peptide or an irrelevant HIV peptide. The CD8+ T cells were assessed for IFN-γ
production in order to determine the recognition of the endogenously processed MART-126–35 epitope
(Figure 2a). MART-1-specific T-cells induced by Ad-5/3-MART-1 and Ad5-MART-1 transduced
MoDCs or by MART-126–35L peptide-loaded MoDCs were all capable of recognizing the HLA-A2+
JY target cells loaded with the specific MART-126–35L peptide with high specificity, but not the
HIV peptide-loaded JY targets. In addition, the CD8+ T cells also exclusively recognized the
HLA-A2+MART-1+ Mel-AKR cell line, demonstrating their ability to specifically recognize the
endogenously processed MART-1 epitope restricted by HLA-A2. MART-1-specific CD8+ T cells
stimulated by Ad5/3-MART-1-transduced MoDCs produced higher levels of IFN-γ in response to
Mel-AKR than those stimulated by Ad5-MART-1-transduced MoDCs or MART-126–35L-pulsed MoDCs;
however, this difference did not reach statistical significance (Figure 2a). Note that IFN-γ production
in response to MART-1 peptide loaded targets was significantly elevated in Ad5/3 primed CD8+ T
cells over that of their Ad5 primed counterparts (Figure 2a).
3.3. Functional Avidity of MART-126–35L-Specific CD8+ T Cells Primed by Ad5/3-MART-1 Targeted MoDCs
Expanded MART-1-specific CD8+ T cells that were induced through stimulation with either
Ad5/3 transduced or peptide-loaded MoDCs were evaluated for their functional avidity. Primed CD8+
T cells were co-cultured with HLA-A2+ JY cells loaded with different concentrations of MART-126–35L
peptide. Intracellular IFN-γ production by MART-126–35L tetramer-isolated CD8+ T cells was used as
a read-out of this assay. In two out of three donors tested, MART-1-specific CD8+ T cells induced by
Ad5/3-MART-1-transduced DCs demonstrated a higher functional avidity than CD8+ T cells induced
by MART-126–35L peptide pulsed DCs (Figure 2b, Exp-1 and Exp-3). In the other donor tested, the CD8+
T cells primed by MART126–35L peptide-loaded MoDCs displayed a slightly higher functional avidity
(Figure 2b, Exp-2). Based on three separate experiments with three independent donors, comparable
production levels of IFN-γ reflected the equivalent recognition of the MART-126–35L epitope by CD8+
T cells primed with MoDCs transduced by Ad5/3-MART-1, encoding full-length MART-1, or with
MART-126–35L peptide-pulsed MoDCs. Figure 2b also shows the combined data of three separate
priming experiments, displaying relative IFN-γ percentages, with percentages for the highest tested
concentration (10 µM) set at 100% per condition. The actual percentages of IFN-γ producing Tm+
CD8+ T cells for the 10 µM concentration were 91.2 ± 7.7% and 80.2 ± 13.2% for MART-126–35L
peptide-generated and Ad5/3-MART-1-generated CTL, respectively. The dotted lines in Figure 2b
indicate the EC50 value (half-maximum) of IFN-γ production, which was slightly lower, though not
statistically significant, for Ad5/3-MART-1 primed CD8+ T cells than for MART-126–35L peptide-primed
CD8+ T cells when looking at the combined data of three experiments.
3.4. Melanoma Cytolysis by T Cells Primed with Ad5/3-MART-1 Transduced MoDCs
In agreement with the IFN-γ release experiments, MART-1-specific CD8+ T cells generated
through Ad5/3-MART-1 transduced or MART-126–35L peptide-pulsed MoDCs showed specific cytolytic
activity against the HLA-A2+ MART-1+ MEL-AKR tumor cell line, but not the HLA-A2− MART-1+
MEL-JKO cell line (Figure 2c). Data shown are average cytotoxicity percentages for two independent
CTL donors. A third experiment also showed specific cytotoxicity, but for both the Ad5/3-MART-1
CTL and MART-126–35L peptide CTL maximum killing was below 10%.
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Figure 2. Ad5/3-MART-1 cytotoxic T lymphocyte specificity, avidity and cytotoxicity. (a) MART-1
specific CD8+ T cells primed by Ad5-MART-1, Ad5/3-MART-1-transduced MoDCs or MART-126–35L
peptide-loaded MoDCs produced IFN-γ upon recognition of endogenously processed MART-1 protein
in the context of HLA-A2 (MEL-AKR) or specific peptide-loaded HLA-A2+ JY cells, but were unable to
recognize irrelevant peptides or HLA-A2− MART-1+ (MEL-JKO) or HLA-A2+ MART-1− (U251) targets.
Combined results from three priming experiments with independent donors are shown. A two-way
ANOVA with Tukey multiple comparison analysis was performed, showing statistically significant
differences in the recognition of MART-126–35L-loaded JY cells by Ad5/3-MART-1 induced CD8+ T cells
(p < 0.05) or MART-126–35L peptide-induced CD8+ T cells (p < 0.001) compared to Ad5-MART-1-induced
CD8+ T cells. (b) HLA-A2+ JY cells were loaded with titrated MART-126–35L peptide as indicated and
cultured with Ad5/3-MART-1 primed or MART-126–35L peptide primed CD8+ T cells for 4–5 h in the
presence of golgiplug. Avidity was assessed by means of intracellular IFN-γ staining. IFN-γ release
upon recognition of JY cells loaded with 10 µM peptide was set at 100% for both Ad5/3-MART-1 and
MART-126–35L peptide-induced CD8+ T cells. Graphs are shown for three separate experiments with
MART-126–35L specific CD8+ T cells generated from independent donors, as well as a graph showing
the combined values of experiment 1 + 2 + 3 (bottom right) (means ± SEM) Half maximum release
levels are indicated by the dotted lines. (c) Expanded and isolated MART-1 specific CD8+ T cells
primed by Ad5/3-MART-1 transduced MoDCs (left) or MART-126–35L peptide-loaded MoDCs (right)
were able to kill MART-1 expressing tumor cells in a HLA-A2 restricted manner. Averaged data from
two separate experiments with CD8+ T cells derived from two different HLA-A2+ donors are shown
(mean ± SEM).
3.5. Superior Expansion of MART-1 Specific CD8+ T Cells Residing in Melanoma SLN Upon Ad5/3-MART-1
Infection as Compared to Ad5-MART-1
The ability of Ad5 and Ad5/3 to selectively and efficiently transduce DCs was previously
evaluated by our group in ex vivo LN suspensions. It was shown that Ad5/3-eGFP transduction
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of DCs in melanoma-draining SLN led to significantly enhanced eGFP transgene expression levels
compared to Ad5-eGFP-mediated transduction, especially of the more mature skin-derived, migratory
DC subsets present in skin-draining SLN [41]. Regarding the melanoma SLN as the primary site for
melanoma-specific T cell induction, here we investigated the ability of Ad5/3-MART-1 transduced
SLN-APCs to expand melanoma-reactive T cells residing within SLN single-cell suspensions as
compared to Ad5-MART-1. Our data showed increased frequencies of MART-1-specific CD8+ T cell
(recognizing the MART-126–35 epitope) in SLN, upon ex vivo stimulation through Ad5/3-MART-1
transduction as compared to Ad5-MART-1 (Figure 3). Figure 3a shows the frequencies of MART-1 Tm+
CD8+ T cells from n = 5 SLN after the primary stimulation. Figure 3b shows for one donor the precursor
frequency of MART-126–35L Tm+ CD8+ T cells within the single cell suspension and the corresponding
frequencies after the primary ex vivo stimulation using Ad5-MART-1 or Ad5/3-MART-1. Graphs in
Figure 3c,d show the primary stimulation and further re-stimulation data from two donors, with six
bulk cultures per donor. Due to restrictively low rates of MART-1 Tm+ CD8+ T cells in these short-term
cultures, further functional assays could not be performed.
Figure 3. In situ stimulation of MART-1 specific CD8+ T cells in melanoma sentinel lymph nodes
(SLNs). Stimulation of pre-existing MART-1 specific CD8+ T cells present within metastasis negative
melanoma sentinel lymph node single-cell suspensions (HLA-A2+) through ex vivo infection using
either Ad5-MART-1 or Ad5/3-MART-1. (a) Combined data showing MART-126–35L Tm+ CD8+ T cells
of in total 28 bulk cultures upon primary stimulation (n = 5 SLN donors) with bulk cultures from
the same donor indicated with the same filling patterns. An unpaired Student t test was performed
between the Ad5-MART-1 and Ad5/3-MART-1 conditions; (b) Precursor frequency of MART-126–35L
Tm+ CD8+ T cells in SLN donor-5 compared to frequencies after one round of ex vivo stimulation
(d10) with Ad5-MART-1 or Ad5/3-MART-1; (c) Depicted are the percentages of MART-126–35L Tm+
cells from CD8+ T cells after the primary stimulation with Ad5-MART-1 or Ad5/3-MART-1 (Day 11)
and after one round of re-stimulation with irradiated MART-126–35L loaded HLA-A2+ JY cells (Day 18)
(n = 2 donors 1+2, 6 bulk cultures per donor per condition). (d) Donors depicted in (c) separated for
Ad5-MART-1 and Ad5/3-MART-1 stimulation showing increased or decreased frequencies of MART-1
Tm+ cells of CD8+ T cells between the primary (1st stim) and secondary (2nd stim) ex vivo stimulation.
In this figure Ad5 = Ad5-MART-1, Ad5/3 = Ad5/3-MART-1.
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4. Discussion
With the recent, accumulating successes of checkpoint inhibitors in treating advanced stage
melanoma as well as a growing number of other tumor indications [1,2,43], new challenges have
emerged. Firstly, predictive biomarkers need to be identified that can aid in selecting those patients
that are most likely to respond to these type of therapies. Secondly, the cancer field is challenged to find
combination treatments that will result in increased response rates on immunotherapy, particularly for
those patients that have low frequencies of type-1 and effector memory tumor-infiltrating lymphocytes.
With this challenge, a renewed interest in vaccine strategies has emerged that can induce or expand
antitumor effector T cells in vivo, leading to increased tumor-infiltrating T cell numbers [44]. One of the
first steps of getting T cells into the tumor microenvironment is efficient presentation of tumor-antigens
by DCs and subsequent priming of naïve T cells [45]. We investigated whether the use of a MART-1
expressing chimeric Ad5/3, targeting CD80 and CD86 on DCs, could result in efficient priming and
activation of melanoma specific CD8+ T effector cells both in vitro and in a human ex vivo SLN model.
Indeed, DCs transduced by this CD80/CD86-targeted Ad vector significantly enhanced both the
priming efficiency of MART-1 specific CD8+ T effector cells and expansion of TAA-reactive CD8+
T cells in SLN, as compared to DCs transduced by a MART-1 expressing serotype-5 adenoviral vector
(Ad5-MART-1). Moreover, results showed that the generated MART-1-recognizing CD8+ T cells
were fully functional and capable of recognizing and killing melanoma tumor cells, as effectively
as MART-1 specific CD8+ T cells primed by MART-126–35L peptide-pulsed DCs. CD8+ T cells from
all test conditions were able to specifically recognize HLA-A2+ targets exogenously loaded with
the MART-126–35L epitope or a HLA-A2+ melanoma cell line expressing endogenously processed
MART-1 epitopes. Of note, CD8+ T cells primed with Ad5/3-MART-1-transduced DCs showed a trend
towards higher production levels of the immunostimulatory cytokine IFN-γ in response to HLA-A2+
melanoma cells expressing MART-1 as compared to the other in vitro primed CD8+ T cells. Moreover,
the CD8+ T cells primed by Ad5/3-targeted DCs also demonstrated specific cytotoxic activity against
melanoma cells expressing endogenously processed MART-1 epitopes in an HLA-A2-restricted fashion.
As a general consensus, high avidity CD8+ T effector cells mediate better antitumor T cell responses
with higher efficacy to eliminate tumor cells [46].
MoDCs pulsed with the immunodominant HLA-A2-restricted epitope MART-126–35L,
an altered peptide ligand with high affinity major histocompatibility complex-binding properties,
could significantly induce high frequencies of MART-1 specific CTLs [39]. However, the fact that
Ad vectors encoding the full-length MART-1 protein were used for DC transduction and all our
read-out assays were conducted with a single MART-1 epitope, reveals that highly efficient antigen
processing and presentation occurred in the transduced DCs for subsequent CD8+ T cell stimulation.
The frequencies of MART-126–35L Tm+ CD8+ T cells present in the bulk cultures upon Ad5/3-MART-1
stimulation, likely under-represents the actual frequencies of MART-1 protein specific effector CD8+ T
cells in these cultures. The enhanced cytolysis of Mel-AKR tumor cells by Ad5/3-MART-1 induced
CTLs is remarkable and also suggests very efficient recognition of the endogenously processed
MART-126–35wt epitope. In this context, the use of recombinant Ad encoding for the full-length
MART-1 sequence has definite benefits over the use of a single peptide epitope, as multiple epitopes
could be presented on various HLA alleles, including Th and CTL epitopes, and applied as a vaccine
without HLA restrictions. Furthermore, from a clinical perspective, in vivo administration of short
peptides like the MART-126–35L epitope could lead to their direct binding to major histocompatibility
(MHC) molecules on the surface of non-professional APCs, thereby potentially inducing tolerance or
anergy in the absence of correct co-stimulation [47]. In addition, the limited or absent tertiary structure
of short peptides makes them susceptible to exopeptidase-mediated degradation [22,48]. In contrast,
adenoviruses are stable gene delivery vehicles in vivo, promoting optimal antigen presentation by
DCs in secondary lymphoid organs or at the site of the tumor.
In vivo DC targeting approaches often focus on targeting easily accessible peripheral DCs in skin.
However, intradermally delivered Ad viruses may also drain directly to LNs and target DC subsets
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there [49]. In melanoma, DC populations within the SLN have been reported to express lower levels of
activation markers because of a generally less activated phenotype compared to DCs in second-line
melanoma-draining LNs [23,30]. In this context, SLN may be characterized by their restrained ability
to generate protective anti-tumor T cell immunity. We however previously showed that especially
the more matured, skin-migrated DC subsets present within SLN, still express sufficiently high levels
of the co-stimulatory molecules CD80 and CD86, to be efficiently targeted by Ad3 knob-containing
viruses [29,41]. The results from the current study show that ex vivo transduction of DCs in SLN cell
suspensions from melanoma patients by Ad5/3-MART-1 facilitated the expansion of TAA-specific
CD8+ T cells leading to higher frequencies of MART-126–35L-specific T cells compared to the wild-type
Ad5-MART-1. Unfortunately, it was not possible to evaluate these MART-126–35L-specific T cells
for their functional capacities, since expansion of T cells in these short-term cultures did not reach
numbers compatible with functional assays. T cell receptor (TCR) sequencing studies could explore
whether the expanded MART-1 specific T cells within such SLN suspensions represent clonal T cell
populations. Moreover, since no functional assays could be performed with the T cells expanded in
these cultures, we do not know whether those cells are functionally capable of producing IFN-γ and
killing their target cells similarly to the MART-126–35L specific T cells generated through in vitro priming
experiments using MoDC. Their expansion as well as functional capabilities could potentially be
improved through the addition of checkpoint inhibitors like anti-CTLA4 and/or anti-PD-1. However,
as with all checkpoint inhibitor-containing immunotherapy regimens, the development of any immune
adverse events should be closely monitored should such combination therapies be tested in vivo.
Although chimeric fiber-modified Ad5/3 appears to be an appealing vaccine vector, various
challenges relating to its clinical translation need to be addressed in order to obtain clinical
proof-of-concept [32]. The principal concern is related to the fact that Ad5- or Ad2-based vaccines
can often only be applied once as an immediately induced or enhanced Ad-specific immune response
will neutralize a booster vaccine [25,32]. This does not only involve pre-existing Ad-neutralizing
Abs, but also pre-existing Ad-specific CTL responses. Indeed Molinier-Frenkel et al. [50] have shown
that despite deleting adenoviral regions (E1, E1 + E2, or E1 + E4), anti-viral CTL responses are
still activated, already upon the first injection in individuals with pre-existing immunity. Since in
our system, the Ad5/3-MART-1 is targeted to CD80/CD86-expressing DCs, this could result in the
stimulation of Ad-specific T cell responses through the presentation of viral antigens, and subsequent
killing of the Ad-transduced DCs and quenching of the anti-MART-1 response over time. We did
not assess the magnitude of the Ad-directed CD8+ T cell response in the SLN cultures. We anticipate
that the proposed local (intradermal) administration of Ad-vectors targeting DC subsets in the
tumor/skin-draining lymph nodes will be less hampered by anti-Ad cellular immune responses
as it was shown that this route of administration in human healthy individuals, using Ad5 vectors,
resulted only in mild to moderate local cellular immune responses, even in immunized individuals [51].
Moreover, to overcome this hurdle of pre-existing immunity, scientists have shifted their focus from
homologous to heterologous prime-boost strategies. In this case, Ads of different serotypes are used for
the priming or the boosting step. It has been found that heterologous prime-boost strategies led to more
robust Th1 cellular responses in mice and non-human primates [33,34]. Kahl et al. [35] demonstrated
that priming with Ad5 was most efficient when a rare Ad serotype with low seroprevalence in the
general population, such as Ad28, was used as a booster vaccine. In this context, many chimeric
Ad5 vectors have been designed by replacing the Ad5 fiber domain or just the fiber knob with a fiber
of less common human serotypes [52–54] or of non-human serotypes [55–57]. The Ad3 serotype is
one of the most widely studied for altering Ad5 tropism with relatively low seroprevalence [58] and
use of CD80/CD86 as primary docking receptors [28,32]. Our data suggest chimeric fiber-modified
Ad5/3, with high efficiency in DC transduction, to be a good candidate for prime-boost vaccine
strategies. For this purpose, a panel of different, but equally efficient DC-targeting Ad vectors, such as
Ad3 [29,34,35], Ad35 [59], and CD40-Ad5 [39,60], should be tested in different prime-boost combination
vaccination schemes in order to promote the generation of an even more robust antigen-specific T cell
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response [61–65] without collateral and restrictive anti-Ad-immunity. As it has been reported that Ad5
knob-swap variants could still be neutralized by Ad5-specific antibodies that mostly bind the Ad5
hexon protein [39,66,67], hexon-chimera vectors [68–70] or the different wild type (wt) serotype vectors
(e.g., Ad3, Ad11, Ad35) might be more efficacious for clinical use [71]. Combination of Ad-based
vaccines with protein, DNA or RNA vaccines, or bacterial or other viral vectors could also be used in
prime-boost strategies in order to eliminate negative effects of anti-Ad immunity [72]. In addition to
targeting DCs via CD80/CD86, Ad3-based oncolytic adenoviruses are currently being developed for
clinical use to directly target the tumor microenvironment, through binding of Ad3 to tumor-expressed
desmoglein-2, a receptor used by various type B adenoviruses and expressed on several cancer
types [29,41,73–75]. These oncolytic adenoviruses are also being armed to include DC-activating
components such as CD40-ligand [76]. In conclusion, Ad3-based viruses, be it replication-incompetent
or competent, seem very useful in promoting antitumor effector T cell responses either via oncolysis or
targeting to DCs and could be used combined with immune checkpoint inhibitors like anti-CTLA-4
or anti-PD(L)-1 to overcome the suppression of tumor-specific T cells during the priming phase
(anti-CTLA-4) or the effector phase in the tumor microenvironment (anti-PD-(L)1).
5. Conclusions
Collectively, our data showing the improved expansion of MART-1 specific CD8+ effector T cells
both from naïve blood and from melanoma-draining SLN support the use of Ad3-based viruses as an
in vivo DC-targeting vaccine vehicle in patients with melanoma.
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